8-K: Azitra Inc. Reports Q1 2024 Financial Results and Provides Business Update

Azitra, Inc., a clinical-stage biopharmaceutical company, announced its Q1 2024 financial results and provided updates on its clinical programs, including progress on ATR-12 and ATR-04.

Summary

• Azitra, Inc. reported a net loss of $2.9 million for the quarter ended March 31, 2024, compared to a net loss of $2.5 million for the same period in 2023.
• The company's research and development expenses increased to $1.5 million in Q1 2024 from $0.8 million in Q1 2023.
• General and administrative expenses also increased to $1.5 million in Q1 2024, up from $0.8 million in the same period last year.
• Azitra had $3.0 million in cash and cash equivalents as of March 31, 2024.
• The company completed a follow-on public offering in February 2024, raising $5.0 million in gross proceeds.
• Azitra is advancing its ATR-12 Phase 1b trial for Netherton syndrome, with initial safety data expected before year-end.
• The company is also progressing with ATR-04, a treatment for EGFR inhibitor-induced rash, with an IND submission planned for mid-2024.
• Azitra has a Joint Development Agreement with Bayer for eczema-prone skin products, with discussions for a license agreement ongoing.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials and partnerships, the increased net loss and decreased revenue are concerning. The company is making progress but is still in an early stage and faces significant risks.

Positives

• Azitra is making significant progress in advancing its clinical programs, particularly ATR-12 and ATR-04.
• The successful completion of a $5.0 million follow-on public offering strengthens the company's financial position.
• The issuance of a U.S. patent enhances Azitra's intellectual property portfolio.
• The ongoing discussions with Bayer for a license agreement are a positive development for the company's partnership strategy.
• Preclinical data for ATR-12 shows promising results for the treatment of Netherton syndrome.
• The company has identified patients for the ATR-12 Phase 1b trial and expects to announce initial safety data before year-end.

Negatives

• The company's net loss increased to $2.9 million in Q1 2024, compared to $2.5 million in the same period last year.
• Service revenue decreased to $0 in Q1 2024, compared to $113,300 in Q1 2023.
• Both R&D and G&A expenses have increased significantly year-over-year.
• The company's cash and cash equivalents are at $3.0 million as of March 31, 2024.

Risks

• The company may fail to successfully complete its Phase 1b trial for ATR-12 and pre-clinical studies of other product candidates.
• Azitra's product candidates may not be effective.
• There may be delays in regulatory approval or changes in the regulatory framework.
• The company's estimation of addressable markets may be inaccurate.
• Azitra may fail to timely raise additional required funding.
• More efficient competitors or more effective competing treatments may emerge.
• The company may be involved in disputes surrounding the use of its intellectual property.
• Azitra may not be able to attract and retain key employees and qualified personnel.
• Earlier study results may not be predictive of later stage study outcomes.
• The company is dependent on third-parties for some or all aspects of its product manufacturing, research, and preclinical and clinical testing.

Future Outlook

Azitra anticipates key data readouts, including initial safety data for ATR-12 before year-end, and plans to submit an IND for ATR-04 by mid-2024, with the goal of initiating a trial before year-end. The company also expects to execute a licensing agreement with Bayer.

Management Comments

• Azitra has made significant progress in 2024, advancing towards crucial milestones and potentially transformative catalysts, including key data readouts.
• Our lead program, ATR-12, has secured clinical sites and identified Netherton syndrome patients for enrollment in our 12-patient, Phase 1b clinical trial, which will assess safety, tolerability, and efficacy endpoints.
• We expect to announce initial safety data before year end.
• We also announced novel preclinical findings at ASGCT related to ATR-12, showcasing its potential for superior LEKTI delivery compared to topical LEKTI application when administered to ex vivo human skin.
• Moreover, preclinical evidence suggests that ATR-12 can markedly reduce IL-36g, a pro-inflammatory cytokine implicated in Netherton syndrome, further validating the potential of our approach.
• Following a successful pre-IND meeting with the FDA, we plan to submit an IND for a Phase 1b trial by mid-2024.
• Subject to FDA clearance, we aim to initiate the trial before year-end in patients undergoing a rash due to EGFR inhibitors.
• With a robust pipeline, strong partnerships, and upcoming value-driving milestone announcements, we believe Azitra is poised to revolutionize the treatment landscape for severe skin conditions and deliver significant shareholder value in the near future.

Industry Context

Azitra's focus on precision dermatology and the development of therapies for rare skin conditions aligns with the growing trend in the biopharmaceutical industry towards personalized medicine and addressing unmet medical needs. The company's partnerships and focus on novel treatments position it to potentially capture a significant share of the market for severe skin conditions.

Comparison to Industry Standards

• Azitra's R&D spending of $1.5 million for the quarter is relatively low compared to larger pharmaceutical companies, but is typical for a clinical-stage biotech company.
• The company's net loss of $2.9 million is also typical for a company at this stage of development, as they are investing heavily in research and clinical trials.
• The $5.0 million raised in the follow-on public offering is a positive step for the company's financial stability, but they will likely need to raise additional capital in the future to fund their clinical programs.
• The estimated peak sales opportunity of ~$250 million for ATR-12 and >$1B for ATR-04 are significant, but these are estimates and will depend on the success of clinical trials and regulatory approvals.
• Companies like Dermavant Sciences and Arcutis Biotherapeutics are also focused on developing treatments for dermatological conditions, and Azitra will need to compete with these companies in the market.

Related Party Transactions

• The company generated $0 service revenue from related parties during the quarter ended March 31, 2024, compared to $113,300 for the comparable period in 2023.

Stakeholder Impact

• Shareholders may be impacted by the company's increased net loss and the need for future capital raises.
• Employees may be impacted by the company's financial performance and the need to achieve clinical milestones.
• Patients with Netherton syndrome and EGFR inhibitor-induced rash may benefit from the company's clinical programs if successful.
• Bayer, as a partner, may be impacted by the progress of the Joint Development Agreement and the potential licensing agreement.

Next Steps

• Publication of preclinical data at the ASGCT Annual Meeting on May 10, 2024.
• Publication of preclinical data at the SID Annual Meeting on May 17, 2024.
• Publication of preclinical data at the ASCO Annual Meeting on May 23, 2024.
• IND submission for ATR-04 in mid-2024.
• First patient dosed in the 12-patient clinical trial for ATR-12.
• Initial clinical safety data for ATR-12 in late 2024.
• First patient dosed in first-in-human clinical trial for ATR-04 in late 2024 or early 2025.
• Execution of a licensing agreement with Bayer.

Key Dates

Keywords

biopharmaceutical, dermatology, clinical trial, Netherton syndrome, EGFR inhibitor, ATR-12, ATR-04, FDA, patent, Bayer, licensing, research and development, financial results, public offering